Innovation Pharmaceuticals Reports on Successful Phase II Trial of Brilacidin-OM for Oral Mucositis

Innovation Pharmaceuticals Reports on Successful Phase II Trial of Brilacidin-OM for Oral Mucositis

Source: 
CP Wire
snippet: 

Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report further data analysis from its successfully completed Phase 2 clinical trial of Brilacidin-OM (see NCT02324335) for the indication of decreasing the incidence of Severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation.